Breaking News

NanoImaging Services Collaborates with Viva Biotech to Offer an Integrated CryoEM Gene-to-Structure Workflow to Streamline Target Discovery

This strategic partnership will bring together NanoImaging Services’ industry-leading expertise and innovation in high-resolution structural enablement by cryoEM and Viva Biotech’s world leading drug discovery platform to enable the management of projects from construct design through to final maps and subsequent protein supply.

Aegis Launches Infectious Disease Testing

Real-time PCR can detect low-level infections by amplification of specific genomic regions from a small amount of nucleic acid within a few hours.

Verifique™ Launches As the Fastest & Most Accurate At-home Drug Testing Kit on the Global Market

Verifique is the fastest and most accurate at-home drug testing kit on the global market, providing results in under 30 seconds.

New Acquisitions & Mergers

KSL Biomedical, Inc. Announces Expansion to Canada with Acquisition of Pulse Scientific

Pulse Scientific is located on the shores of Lake Ontario between Toronto and Niagara Falls in Burlington, Ontario

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress.

Growth / Development

Sequential Skin Raise US $1.65M in Oversubscribed Seed Round

This latest investment brings the total venture funding raised by Sequential Skin to US $2.15M in 2021.

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering

Clinical Trials

Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 Against COVID-19

Statistically significant reduction in time to the improvement of respiratory symptoms. Fewer hospitalizations and intensive care admissions.

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, MD, Associate Professor of Neurology and Principal Investigator.

Executives on the Move

Mike Hicks Appointed Chief Technology Officer of ValGenesis

Before joining ValGenesis, Mike served as the Chief Product & Technology Officer of Intelex Technologies and currently serves as a growth advisor for multiple startups.

BioMarin New Hires

Consistent with BioMarin's regular planning, Dr. Bernstein will succeed Geoff Nichol M.B. Ch.B., MBA, FRACP, who has served for almost five years making significant contributions to the Company's clinical development program including three product approvals.  Dr. Nichol will remain at the Company to assist with the transition and to serve in an advisory capacity on late stage clinical programs. 

Genprex Appoints Mark S. Berger, M.D. as CMO & Hemant Kumar, Ph.D. as Chief Manufacturing & Technology Officer

“It is my privilege and pleasure to welcome Mark and Hemant to our management team. Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner, Chief Executive Officer.

FDA Cleared Devices & News

OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel

The Acuitas® AMR Gene Panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens.

FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals

"The FDA is seeking to improve transparency by engaging early in the development process and informing industry of our draft recommendations now, while the industry is still taking shape, as we are receiving applications seeking approval of ACTPs for use in animals," said Dr. Steven Solomon, director of the FDA's Center for Veterinary Medicine.

Pharma